Hexavalent vaccine
Infanrix hexa vaccine (one of two brands of the 6-in-1 vaccine used in the UK)[1] | |
| Combination of | |
|---|---|
| Diphtheria vaccine | Vaccine |
| Pertussis vaccine | Vaccine |
| Tetanus vaccine | Vaccine |
| Hepatitis B vaccine | Vaccine |
| Polio vaccine | Vaccine |
| Haemophilus vaccine | Vaccine |
| Clinical data | |
| Trade names | Infanrix hexa, Hexyon, Vaxelis, others |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
A hexavalent vaccine, or 6-in-1 vaccine, is a combination vaccine with six individual vaccines conjugated into one, intended to protect people from multiple diseases.[1][9] The term usually refers to the children's vaccine that protects against diphtheria, tetanus, pertussis, poliomyelitis, haemophilus B, and hepatitis B,[1][9] which is used in more than 90 countries around the world including in Europe, Canada, Australia, Jordan, and New Zealand.[1][10]
- ^ a b c d "6-in-1 Vaccine". Vaccine Knowledge Group. 29 June 2018. Archived from the original on 3 July 2018. Retrieved 3 July 2018.
- ^ a b "Vaxelis APMDS". Therapeutic Goods Administration (TGA). 6 April 2022. Retrieved 24 April 2022.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
- ^ Cite error: The named reference
Hexavac EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Hexyon EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Vaxelis EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Hexacima EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Infanrix Hexa EPARwas invoked but never defined (see the help page). - ^ a b Orsi A, Azzari C, Bozzola E, Chiamenti G, Chirico G, Esposito S, et al. (June 2018). "Hexavalent vaccines: characteristics of available products and practical considerations from a panel of Italian experts". Journal of Preventive Medicine and Hygiene. 59 (2): E107 – E119. PMC 6069402. PMID 30083617.
- ^ Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, Rodríguez-Tenreiro Sánchez C, Martinón-Torres F (August 2018). "New perspectives for hexavalent vaccines". Vaccine. 36 (36): 5485–5494. doi:10.1016/j.vaccine.2017.06.063. PMID 28676382. S2CID 4384043.